Sign in →

Test Code NMRLP Nuclear Magnetic Resonance Lipoprotein Profile, Serum


Specimen Required


Patient Preparation:

1. Fasting overnight (12-14 hours) is required. On night before examination, evening meal should be eaten before 6 p.m. and should contain no fatty foods.

2. Patient must not consume any alcohol for 24 hours before the specimen is collected.

Collection Container/Tube: Red top (serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 1.5 mL

Collection Instructions:

1. Allow isopropyl alcohol (from phlebotomy site prep) to dry thoroughly before venipuncture.

2. Centrifuge and aliquot serum into a plastic vial.


Useful For

Assessment and management of a patient's risk for atherosclerotic cardiovascular disease

 

Identifying residual risk that may be present in some patients on cholesterol targeting treatment

Method Name

Nuclear Magnetic Resonance (NMR)

Reporting Name

NMR Lipoprotein Profile, S

Specimen Type

Serum Red

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Red Refrigerated (preferred) 7 days
  Frozen  14 days
  Ambient  8 hours

Reference Values

≥18 years:

 

LDL Particles:

Desirable: <1,000 nmol/L

Above Desirable: 1,000-1,299 nmol/L

Borderline high: 1,300-1,599 nmol/L

High: 1,600-2,000 nmol/L

Very high: ≥2,000 nmol/L

 

HDL Particles:

Male: >30 mcmol/L

Female: >35 mcmol/L

 

LDL Cholesterol (NMR):

Desirable: <100 mg/dL

Above Desirable: 100-129 mg/dL

Borderline high: 130-159 mg/dL

High: 160-189 mg/dL

Very high: ≥190 mg/dL

 

Reference values have not been established for patients younger than 18 years of age.

Interpretation

Elevated concentrations of low-density lipoprotein particle (LDL-P) are associated with increased risk of atherosclerotic cardiovascular disease.

 

LDL-P is a more accurate indicator of risk when LDL cholesterol is discordantly low.

 

Lower concentrations of high-density lipoprotein particle are associated with increased risk of atherosclerotic cardiovascular disease.

Clinical Reference

1. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013;128(11):1189-1197. doi:10.1161/CIRCULATIONAHA.113.002671

2. Lawler PR, Akinkuolie AO, Ridker PM, et al. Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women. Clin Chem. 2017;63(4):870-879. doi:10.1373/clinchem.2016.264515

3. Akinkuolie AO, Paynter NP, Padmanabhan L, Mora S: High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes. 2014;Jan;7(1):55-63. doi:10.1161/CIRCOUTCOMES.113.000675

4. Tehrani DM, Zhao Y, Blaha MJ, et al. Discordance of ow-density lipoprotein and high-density lipoprotein cholesterol particle versus cholesterol concentration for the prediction of cardiovascular disease in patients with metabolic syndrome and diabetes mellitus. Am J Cardiol. 2016;117(12):1921-1927. doi:10.1016/j.amjcard.2016.03.040

5. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events. J Am Coll Cardiol. 2012;60(6):508-516. doi:10.1016/j.jacc.2012.03.060

6. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002;160:41-48

7. Khera AV, Demler OV, Adelman SJ, et al. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). Circulation. 2017;135(25):2494-2504. doi:10.1161/CIRCULATIONAHA.116.025678

Day(s) Performed

Tuesday,Friday

Report Available

2 to 7 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

83704

LOINC Code Information

Test ID Test Order Name Order LOINC Value
NMRLP NMR Lipoprotein Profile, S In Process

 

Result ID Test Result Name Result LOINC Value
606167 LDL Particles, S 54434-6
606168 HDL Particles, S 49748-7
606169 LDL Cholesterol (NMR), S 2089-1

Forms

If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.